Literature DB >> 23883236

FDG PET/CT in the management of primary pleural tumors and pleural metastases.

Matthew Kruse1, Steven J Sherry, Vasavi Paidpally, Gustavo Mercier, Rathan M Subramaniam.   

Abstract

OBJECTIVE. FDG PET/CT is emerging as an important modality in the evaluation of pleural tumors. PET/CT has an established role in the diagnosis and staging and shows promise in therapy planning, therapy response assessment, and providing prognostic information in patients with malignant pleural mesothelioma. This modality has distinct advantages in characterizing other primary pleural tumors and pleural metastases. CONCLUSION. FDG PET/CT is a useful imaging modality in the management of patients with primary pleural tumors and pleural metastases.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23883236     DOI： 10.2214/AJR.13.10572

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN： 0361-803X            Impact factor:   3.959


  9 in total

Review 1.  Malignant pleural mesothelioma: an update on diagnosis and treatment options.

Authors:  Sanjana Kondola; David Manners; Anna K Nowak
Journal:  Ther Adv Respir Dis       Date:  2016-02-12       Impact factor: 4.031

2.  Imaging modality utilization trends in patients with stage III-IV oropharyngeal squamous cell carcinoma.

Authors:  Yukako Ichimiya; Krishna Alluri; Charles Marcus; Simon Best; Christine H Chung; Rathan M Subramaniam
Journal:  Am J Nucl Med Mol Imaging       Date:  2015-01-15

3.  Quantitative analyses at baseline and interim PET evaluation for response assessment and outcome definition in patients with malignant pleural mesothelioma.

Authors:  Egesta Lopci; Paolo Andrea Zucali; Giovanni Luca Ceresoli; Matteo Perrino; Laura Giordano; Letizia Gianoncelli; Elena Lorenzi; Maria Gemelli; Armando Santoro; Arturo Chiti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-11-18       Impact factor: 9.236

4.  Image-guided interventional radiological delivery of chimeric antigen receptor (CAR) T cells for pleural malignancies in a phase I/II clinical trial.

Authors:  Mario Ghosn; Waseem Cheema; Amy Zhu; Jennifer Livschitz; Majid Maybody; Franz E Boas; Ernesto Santos; DaeHee Kim; Jason A Beattie; Michael Offin; Valerie W Rusch; Marjorie G Zauderer; Prasad S Adusumilli; Stephen B Solomon
Journal:  Lung Cancer       Date:  2022-01-06       Impact factor: 6.081

5.  Stereotactic Comparison Study of (18)F-Alfatide and (18)F-FDG PET Imaging in an LLC Tumor-Bearing C57BL/6 Mouse Model.

Authors:  Yu-Chun Wei; Yongsheng Gao; Jianbo Zhang; Zheng Fu; Jinsong Zheng; Ning Liu; Xudong Hu; Wenhong Hou; Jinming Yu; Shuanghu Yuan
Journal:  Sci Rep       Date:  2016-06-28       Impact factor: 4.379

6.  Preclinical Evaluation and Monitoring of the Therapeutic Response of a Dual Targeted Hyaluronic Acid Nanodrug.

Authors:  Minglong Chen; Wenqi Zhang; Kai Yuan; Mingxiang Bo; Bin Chen; Lu Li; Qingjie Ma; Lei Zhu; Shi Gao
Journal:  Contrast Media Mol Imaging       Date:  2017-07-11       Impact factor: 3.161

7.  Solitary Fibrous Tumors of Chest: Another Look with the Oncologic Perspective.

Authors:  Mert Saynak; Nirmal K Veeramachaneni; Jessica L Hubbs; Dilruba Okumuş; Lawrence B Marks
Journal:  Balkan Med J       Date:  2017-04-06       Impact factor: 2.021

Review 8.  The Prognostic Value of 18F-FDG PET Imaging at Staging in Patients with Malignant Pleural Mesothelioma: A Literature Review.

Authors:  Silvia Taralli; Romina Grazia Giancipoli; Carmelo Caldarella; Valentina Scolozzi; Sara Ricciardi; Giuseppe Cardillo; Maria Lucia Calcagni
Journal:  J Clin Med       Date:  2021-12-22       Impact factor: 4.241

9.  Diffuse Large B-cell Lymphoma Presenting as a Primary Pleural Mass: A Case Report and Literature Review.

Authors:  Gia Thinh D Truong; Zachary A Creech; Kurt V Shaffer; Matthew Merrill
Journal:  Cureus       Date:  2022-03-02
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.